January 2013 Meeting Announcement, Delaware Valley Mass Spectrometry Discussion Group
PLEASE NOTE: We will meet in Mendel 154.
- Topic: "Towards potential biomarkers for pancreatic cancer"
- Speaker:Tony Yeung, Fox Chase Cancer Center
- Date: Monday, January 14, 2013. 6:30 PM
- Time: Social Hour: 6:30 PM.
Talk: 7:30 PM.
Please RSVP to Sergio Nanita email@example.com by Thursday January 10.
- Place: Department of Chemistry, Villanova University (Room 154, Mendel Hall)
Pancreatic cancer is the fourth leading cause of cancer death, with about 38,500 new cases a year and >98% lethality. Moreover, about 2% of people harbor pancreatic cysts. Most cysts are benign but some mucinous cysts can lead to cancer. There are several types of cysts, different stages in each type, and potentially different types of pancreatic cancer. Unfortunately, current biomarkers for the diagnosis and staging of pancreatic neoplasms are neither sufficiently sensitive nor accurate. Our laboratory and others have investigated fluids obtained from the pancreas for potential biomarker proteins that may provide diagnosis and disease staging. We obtained fluids from pancreatic cysts via endoscopy ultrasound fine needle aspiration (EUS-FNA) and from the main pancreatic ducts via needle aspiration at the surgical resection of the pancreas. In pilot studies, we performed GeLC/MS/MS to survey the protein contents and performed qualitative comparisons. The composition of these fluids challenges statistical evaluation because of dilution variations, significant blood contamination, pancreatic enzyme secretion, comorbidities, and instrument dynamic range. However, mass spectrometry allowed quantification of many biomarker proteins using a few microliters of these fluids, an advantage that may translate to earlier diagnosis. Moreover, some protein biomarkers appeared to correlate with patient prognosis after surgery. This presentation will share our experience and discuss future approaches.
Professor Yeung's laboratory is interested in established clinical topics to which basic research and technologies can contribute in a timely manner. His experience includes the UVRABC endonuclease complex DNA repair, the psoralen inter-strand DNA cross-links, the discovery of the CEL I nuclease for mutation detection and for use in TILLING and Zinc Finger nuclease mutagenesis protocols. In recent years, he applied proteomics to biomarker studies of pancreatic cyst fluids and non-cyst cancer, COPD, and hereditary colon cancers arising from one-hit mutations of APC, MSH2, MLH1, and MSH6. He believes in core research resource facility services and contributed to the core director community of ABRF for over 14 years.
Anthony Yeung received his B.S in Chemistry in (June 1973) from Belmont Abbey College in Belmont, NC and his M.Sc. in Biochemistry (June 1975) from Forest University in Winston-Salem, NC. In 1979, Anthony received his Ph.D. in Chemistry from Virginia Polytechnic Institute in Blacksburg, VA working in the laboratory of Dr. R. R. Schmidt studying the cell cycle regulation of an inducible glutamate dehydrogenase of a eukaryotic algae Chlorella. He had seven publications from 1975 - 1979. Anthony was a Postdoctoral Fellow and Research Associate in the laboratory of Dr. L. Grossman from 1979-1983 studying the UvrABC endonuclease complex with four publications.
Dr. Yeung is an Associate Professor with tenure at Fox Chase Cancer Center, Philadelphia, PA from 1983-present and Director, Biochemistry and Biotechnology Facility from 1996-2011. Additionally, He is an Adjunct Associate Professor at Temple University in the Department of Medicine, Philadelphia, PA. His other posts include; Chair, Nucleic Acid Research Group, Association of Biomolecular Resources Facilities (ABRF) 2001-2003. Member, Nucleic Acid Research Group, ABRF 2003-2006 and President ABRF (2011), Executive Board 2008-2012. Anthony served on the Editorial Board, Cancer Genomics and Proteomics 2006-present and the Editorial Board, FASEB Journal 2005-present. Advisor for the Board of the FASEB Society 2009. Member, Diversity Council of the Fox Chase Cancer Center 2010.
Please send any comments, corrections, or suggestions to
This page has been accessed
times since 9/15 /96 .
Last Updated 9/24/2012